Out-Licensing: How hard is it, really?
Is out-licensing difficult? Yes, of course it is. But how difficult is it? Is this something which can be quantified? And, why would we want to quantify this anyway? These…
Menu
LIME: The Secret to Better Out-Licensing?
The humble lime...sour, sweet, juicy, and an essential ingredient in many desserts and beverages. Lime also (supposedly) has many health benefits, including weight loss, improved digestion, and improved skin. But…
Thoughts Leading Up To #BIO2017
#BIO2017 is days away. What can we expect? Crowded Partnering - By our unofficial count, the number of companies registered for One-on-One Partnering exceeds the number from San…
When Does BIO Start?
BIO starts in June, right? Wrong. Perhaps BIO starts in late April, when partnering opens? Sorry. Wrong again. BIO started the moment you decided to…
Is My Asset Licensable?
This is a good question...a question which lacks a simple answer without quite a bit of analysis. We audit out-licensing processes, and there are times when the answer is…
Looking Backward, Looking Forward
I believe it is fair to say that 2016 was a bit unusual. Thinking about the terminology many of us learned last year leads us to that conclusion: snowflake,…
On Catamarans, Elections, and #BIOEurope
BIO Europe was, yet again, an excellent conference for Lacerta Bio. Having the US election on television screens in the Exhibition Hall made for some surreal moments and discussions. Not a…
University Technology Transfer: Change is Needed
A few weeks ago, we attended the first annual Commercializing Biotech Innovation Conference in Syracuse, New York. The conference was held in the very new Central New York Biotech Accelerator in Syracuse (which is…
HIV/AIDS: Growing Unmet Need & Declining Interest?
In our last post, we presented a model which helps us aggregate a series of variables which, in turn, help us understand why certain therapeutic areas or indications are of greater interest from a licensing perspective than others.
Our aim with this model is to help companies with licenseable assets to frame their “stories” in a way which is compatible with how potential partners approach evaluation and decision-making.
Our first attempt at applying this model is for the HIV/AIDS market. During the 1990s, stories about AIDS were a daily occurrence on the nightly news. Images of celebrities fighting and dying from AIDS seemed to be everywhere. Rock Hudson, Freddy Mercury, Anthony Perkins…the list of celebrities who succumbed to complications from this disease seemed endless.
But what about today? Are there Unmet Needs which can be satisfied via novel therapeutics? And, if so, are they being funded and developed? Are there multinational companies with a stated interested in licensing these innovations once they are sufficiently mature?
In this post, we take a look at these questions.
On Triumvirates and Licensing
A triumvirate is a three-person (or three-group) organization which is established for a specific administrative task(s). In Ancient Rome, the First Triumvirate was established between Julius Caesar, Pompey the…